Sarissa Capital Acquisition Corp. announced the pricing of its $175 million IPO this evening and its units are expected to begin trading on the Nasdaq under the symbol “SRSAU” tomorrow, Wednesday, October 21.
The new company aims to combine with a healthcare target with strong intellectual property and the ability to benefit from capital restructuring. Sarissa is led by Chairman and CEO Alexander Denner, President Eric Vincent, CFO Patrice Bonfiglio, and Senior Managing Directors Mark DiPaolo, Odysseas Kostas, Simos Simeonidis
Total SPAC deal count for 2020 year-to-date is now 148 with $56.25 billion in gross proceeds raised. This offering is expected to close on Friday, October 23.
Cantor Fitzgerald & Co. is serving as the sole book running managers for the offering. Willkie Farr & Gallagher LLP is serving as Issuer’s Counsel with Ellenoff Grossman & Schole LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company LLC is acting as trustee.